Studies
| Study First Submitted Date | 2019-08-14 |
| Study First Posted Date | 2019-08-19 |
| Last Update Posted Date | 2022-04-11 |
| Verification Month Year | April 2022 |
| Verification Date | 2022-04-30 |
| Last Update Posted Date | 2022-04-11 |
Browse Interventions
| Sequence: | 96223740 | Sequence: | 96223741 | Sequence: | 96223742 | Sequence: | 96223743 | Sequence: | 96223744 | Sequence: | 96223745 |
| Mesh Term | Docetaxel | Mesh Term | Antineoplastic Agents | Mesh Term | Tubulin Modulators | Mesh Term | Antimitotic Agents | Mesh Term | Mitosis Modulators | Mesh Term | Molecular Mechanisms of Pharmacological Action |
| Downcase Mesh Term | docetaxel | Downcase Mesh Term | antineoplastic agents | Downcase Mesh Term | tubulin modulators | Downcase Mesh Term | antimitotic agents | Downcase Mesh Term | mitosis modulators | Downcase Mesh Term | molecular mechanisms of pharmacological action |
| Mesh Type | mesh-list | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor |
Conditions
| Sequence: | 52279365 |
| Name | Urogenital Neoplasms |
| Downcase Name | urogenital neoplasms |
Id Information
| Sequence: | 40236831 |
| Id Source | org_study_id |
| Id Value | NANODOCE-EA |
Interventions
| Sequence: | 52591580 |
| Intervention Type | Drug |
| Name | NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension |
Browse Conditions
| Sequence: | 193900682 | Sequence: | 193900683 | Sequence: | 193900684 | Sequence: | 193900685 | Sequence: | 193900686 | Sequence: | 193900687 | Sequence: | 193900688 |
| Mesh Term | Urogenital Neoplasms | Mesh Term | Neoplasms by Site | Mesh Term | Neoplasms | Mesh Term | Female Urogenital Diseases | Mesh Term | Female Urogenital Diseases and Pregnancy Complications | Mesh Term | Urogenital Diseases | Mesh Term | Male Urogenital Diseases |
| Downcase Mesh Term | urogenital neoplasms | Downcase Mesh Term | neoplasms by site | Downcase Mesh Term | neoplasms | Downcase Mesh Term | female urogenital diseases | Downcase Mesh Term | female urogenital diseases and pregnancy complications | Downcase Mesh Term | urogenital diseases | Downcase Mesh Term | male urogenital diseases |
| Mesh Type | mesh-list | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor | Mesh Type | mesh-ancestor |
Sponsors
| Sequence: | 48420508 | Sequence: | 48420509 |
| Agency Class | INDUSTRY | Agency Class | INDUSTRY |
| Lead Or Collaborator | lead | Lead Or Collaborator | collaborator |
| Name | NanOlogy, LLC | Name | US Biotest, Inc. |
Central Contacts
| Sequence: | 12034967 |
| Contact Type | primary |
| Name | Gere diZerega, MD |
| Phone | 805-595-1300 |
| gere.dizerega@usbiotest.com | |
| Role | Contact |
Eligibilities
| Sequence: | 30828201 |
| Minimum Age | N/A |
| Maximum Age | N/A |
| Criteria | Inclusion Criteria:
– Exclusion Criteria: – |
| Adult | True |
| Child | True |
| Older Adult | True |
Calculated Values
| Sequence: | 254127157 |
| Registered In Calendar Year | 2019 |
| Were Results Reported | False |
| Has Single Facility | False |
Intervention Other Names
| Sequence: | 26723335 |
| Intervention Id | 52591580 |
| Name | docetaxel |
Responsible Parties
| Sequence: | 28940545 |
| Responsible Party Type | Sponsor |